任春霞, 徐娜, 宋亚琴, et al. Promotion of ovarian tumorigenesis by cancer-associated fibroblasts through Gro-α activated NF-кB nuclear translocation and high expression of VEGF[J]. China Oncology, 2014, 24(5): 321-328.
任春霞, 徐娜, 宋亚琴, et al. Promotion of ovarian tumorigenesis by cancer-associated fibroblasts through Gro-α activated NF-кB nuclear translocation and high expression of VEGF[J]. China Oncology, 2014, 24(5): 321-328. DOI: 10.3969/j.issn.1007-3969.2014.05.001.
Promotion of ovarian tumorigenesis by cancer-associated fibroblasts through Gro-α activated NF-кB nuclear translocation and high expression of VEGF
Background and purpose: Ovarian cancer-associated fibroblasts (CAF) are known to promote epithelial malignancy. The chemoattractant cytokine growth-regulated oncogene alpha (Gro-α) secreted from CAF has been reported to mediate the stroma-epithelia interaction in tumor microenvironment
leading to the development of epithelial ovarian cancer
however
the detailed mechanism is unknown.This study was to determine whether Gro-α could promote ovarian tumorigenesis through activating NF-кB nuclear translocation and VEGF expression in stromal fibroblasts. Methods: ELISA was used to measure the levels of Gro-α in two cancer-associated fibroblasts (CAF) and normal fibroblasts (NF) isolated from high-grade serous ovarian cancer or normal ovarian tissues. CAF conditioned medium (CM) or Gro-α was used to treat NF
while PS1145
the inhibitor of NF-кB
was used as control. NF-кB subunit p65 and vascular endothelial growth factor (VEGF) were detected by Western blot in cells after treatment. Xenograft tumors from nude mice were generated by injection of CAF
NF
or OVCA429 alone or OVCA429 mixed with CAF or NF
and by injection of OVCA429 mixed with NF cells that were treated with or without CAF-CM or Gro-α
or with NF cells that were treated with CAF-CM or Gro-α plus PS1145. The tumor growth curve was measured and the blood vessel density in xenograft tumor tissues was examined by histopathological analysis. Results: The levels of Gro-α were 5-6 folds higher in CAF than in NF. Treatment of NF with CAF-CM or Gro-α stimulated the nuclear translocation of NF-кB subunit p65
and the expression of VEGF
but suppressed the expression of thrombospondin 1
the antiangiogenesis factor
compared with control cells. However
treatment of NF with the NF-кB inhibitor PS1145 reversed these results. The animal assay revealed that CAF stimulated tumor growth stronger than NF
and NF treated with CAF-CM or Gro-α
but not along with PS1145
enhanced xenograft tumor growth through promoting angiogenesis. Conclusion: Ovarian CAF promotes the nuclear translocation of NF-кB and the expression of VEGF through Gro-α autocrine in tumor microenvironment to facilitate angiogenesis and ovarian cancer development.
Preliminary study on the role and mechanism of ISG15 in exosomes in platinum resistance in ovarian cancer
Progress in treatment of gynecological cancer in 2023
Progress in diagnosis and treatment of mucinous ovarian cancer
The latest progress and prospect of gynecological tumor treatment at 2023 ESMO
Progress in diagnosis and treatment of gynecological tumors in 2022
Related Author
Yanan TIAN
Hui ZHENG
Tianqing YAN
Heng ZHANG
Renquan LU
Lin GUO
Zheng FENG
Qinhao GUO
Related Institution
Department of Clinical Laboratory, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University
Department of Gynecological Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University
Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University
Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, State Key Laboratory of Genetic Engineering, Fudan University, Institute of Thoracic Oncology, Fudan University, Department of Oncology, Shanghai Medical College, Fudan University
Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital, Fudan University